Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Glofitamab in a response-adapted approach using interim FDG-PET and ctDNA for primary therapy of DLBCL (GRAIL)

Phase 2 feasibility trial of a ctDNA and FDG-PET interim response-adapted approach for primary therapy of diffuse large B-cell lymphoma. ClinicalTrials.gov lists the study as recruiting.

University Health Network, Toronto